StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report published on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
EVOK stock opened at $4.51 on Wednesday. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $12.32. The business has a fifty day moving average price of $4.60 and a 200-day moving average price of $5.07.
Institutional Trading of Evoke Pharma
An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new position in Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent reporting period.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
- Five stocks we like better than Evoke Pharma
- What is the Nikkei 225 index?
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
- Transportation Stocks Investing
- Vertex’s Pain Drug: Big Pharma’s Next Major Success?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
